Kowalski Szymon, Hać Stanisław, Wyrzykowski Dariusz, Zauszkiewicz-Pawlak Agata, Inkielewicz-Stępniak Iwona
Department of Medical Chemistry, Medical University of Gdansk, Gdansk, Poland.
Department of General, Endocrine and Transplantation Surgery, Medical University of Gdansk, Gdansk, Poland.
Oncotarget. 2017 Jul 22;8(36):60324-60341. doi: 10.18632/oncotarget.19454. eCollection 2017 Sep 1.
The pancreatic cancer is the fourth leading cause of cancer-related death and characterized by one of the lowest five-year survival rate. The current therapeutic options are demonstrating minimal effectiveness, therefore studies on new potential anticancer compounds, with non-significant side effects are highly desirable. Recently, it was demonstrated that vanadium compounds, in particular organic derivatives, exhibit anticancer properties against different type of tumor as well as favorable biodistribution from a pancreatic cancer treatment perspective. In this research, we showed selective cytotoxic effect of vanadium complexes, containing phenanthroline and quinoline as an organic ligands, against human pancreatic ductal adenocarcinoma cell line (PANC-1), compared to non-tumor human immortalized pancreas duct epithelial cells (hTERT-HPNE). Results exhibited that vanadium complexes inhibited autophagy process in selective cytotoxic concentration as well as caused the cell cycle arrest in G2/M phase associated with mitotic catastrophe and increased level of reactive oxygen species (ROS). Moreover, in higher concentration, vanadium derivatives induced a mix type of cell death in PANC-1 cells, including apoptotic and necroptotic process. Our investigation emphasizes the anticancer potential of vanadium complexes by indicating their selective cytotoxic activity, through different process posed by alternative type of cell deaths to apoptosis-resistant cancer cells. Further studies supporting the therapeutic potential of vanadium in pancreatic cancer treatment is highly recommended.
胰腺癌是癌症相关死亡的第四大主要原因,其特征是五年生存率极低。目前的治疗方法效果甚微,因此,对具有极小副作用的新型潜在抗癌化合物进行研究非常必要。最近有研究表明,钒化合物,特别是有机衍生物,对不同类型的肿瘤具有抗癌特性,并且从胰腺癌治疗的角度来看,其生物分布也较为理想。在本研究中,我们发现,与非肿瘤性人类永生化胰腺导管上皮细胞(hTERT-HPNE)相比,含有菲咯啉和喹啉作为有机配体的钒配合物对人胰腺导管腺癌细胞系(PANC-1)具有选择性细胞毒性作用。结果显示,钒配合物在选择性细胞毒性浓度下抑制自噬过程,并导致细胞周期停滞在G2/M期,伴有有丝分裂灾难和活性氧(ROS)水平升高。此外,在较高浓度下,钒衍生物在PANC-1细胞中诱导了一种混合类型的细胞死亡,包括凋亡和坏死性凋亡过程。我们的研究通过表明钒配合物的选择性细胞毒性活性,强调了其抗癌潜力,这种活性是通过替代类型的细胞死亡对凋亡抗性癌细胞产生的不同过程实现的。强烈建议进一步开展支持钒在胰腺癌治疗中治疗潜力的研究。